Immediate Impact
10 standout
Citing Papers
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
2024 Standout
Works of Max Flogegård being referenced
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
2019
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
2012
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Max Flogegård | 45 | 27 | 51 | 67 | 8 | 109 | |
| Ivelise Rijo | 32 | 62 | 22 | 45 | 7 | 123 | |
| Sihem Kaaki | 67 | 10 | 36 | 82 | 8 | 170 | |
| Kayleen Bailey | 78 | 8 | 27 | 29 | 10 | 133 | |
| Joaquín Díaz Mediavilla | 121 | 32 | 156 | 84 | 8 | 195 | |
| Hong L. Tiv | 65 | 13 | 49 | 38 | 7 | 126 | |
| Mark Yan | 33 | 59 | 42 | 95 | 8 | 143 | |
| Evridiki Michalis | 40 | 35 | 30 | 30 | 7 | 81 | |
| Kaitlen Reyes | 31 | 6 | 36 | 82 | 7 | 112 | |
| K. Gary J. Vanasse | 78 | 96 | 75 | 95 | 8 | 171 | |
| G. Barosi | 14 | 35 | 39 | 23 | 10 | 97 |
All Works
Loading papers...